Oxford BioMedica, a gene-based biopharmaceutical company, has announced the initiation of a Phase II collaborative study for TroVax in inoperable metastatic colorectal cancer (CRC) patients.

The randomised, open-label Phase II study will assess anti-5T4 immune responses following treatment, in addition to secondary measures of clinical benefit, including progression-free survival, objective response rate and overall survival.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The study, which is supported by the Experimental Cancer Medicine Centre (ECMC), Cardiff, will be funded by Cardiff University, with some funding awarded by Cancer Research Wales, while Oxford BioMedica will provide TroVax.

Oxford BioMedica chief scientific officer Stuart Naylor said the company believes that TroVax holds promise in the treatment of colorectal cancer and looks forward to working with colleagues at Cardiff University.

"This important study builds on pioneering work undertaken by Dr Godkin and his team and we are pleased to be able to support the transition into Phase II clinical development," Naylor added.

See Also:

The study, entitled TroVax and Cyclophosphamide Treatment in Colorectal Cancer (TaCTiCC), will enrol up to 54 patients with inoperable metastatic CRC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial, by combining TroVax with cyclophosphamide, will determine if the combination approach results in stronger immune responses against 5T4 compared to patients treated with TroVax alone.

Cardiff University principal investigator Andrew Godkin said, "It is a truly translational study in as much as preliminary data have been generated from a series of experiments that started over ten years ago."